TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types

Published:2022-03-27 Issue:6 Volume:14 Page:2868-2879
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Cao Jia-Zheng¹,Yao Gao-Sheng²,Liu Fei³,Tang Yi-Ming²,Li Peng-Ju²,Feng Zi-Hao²,Luo Jun-Hang²,Wei Jin-Huan²

Affiliation:

1. Department of Urology, Jiangmen Central Hospital, Jiangmen, Guangdong, China

2. Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

3. Department of Urology, National Cancer Center, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference30 articles.

1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.;Ribas;Cell,2017

2. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.;Chen;Sci Transl Med,2016

3. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.;Motzer;Nat Genet,2019

4. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.;Peters;Ann Oncol,2019

5. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.;Xu;JAMA Oncol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP